254 related articles for article (PubMed ID: 28941354)
1. Modulatory effect of caffeic acid on cholinesterases inhibitory properties of donepezil.
Agunloye OM; Oboh G
J Complement Integr Med; 2017 Sep; 15(1):. PubMed ID: 28941354
[TBL] [Abstract][Full Text] [Related]
2. Comparative study on the inhibitory effect of caffeic and chlorogenic acids on key enzymes linked to Alzheimer's disease and some pro-oxidant induced oxidative stress in rats' brain-in vitro.
Oboh G; Agunloye OM; Akinyemi AJ; Ademiluyi AO; Adefegha SA
Neurochem Res; 2013 Feb; 38(2):413-9. PubMed ID: 23184188
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
Darreh-Shori T; Hosseini SM; Nordberg A
J Alzheimers Dis; 2014; 39(2):423-40. PubMed ID: 24217282
[TBL] [Abstract][Full Text] [Related]
4. Metformin and its sulphonamide derivative simultaneously potentiateanti-cholinesterase activity of donepezil and inhibit beta-amyloid aggregation.
Markowicz-Piasecka M; Huttunen KM; Sikora J
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1309-1322. PubMed ID: 30251898
[TBL] [Abstract][Full Text] [Related]
5. Donepezil hydrochloride: a treatment drug for Alzheimer's disease.
Sugimoto H
Chem Rec; 2001; 1(1):63-73. PubMed ID: 11893059
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
Shao D; Zou C; Luo C; Tang X; Li Y
Bioorg Med Chem Lett; 2004 Sep; 14(18):4639-42. PubMed ID: 15324879
[TBL] [Abstract][Full Text] [Related]
7. Aqueous extract of Securidaca longipendunculata Oliv. and Olax subscropioidea inhibits key enzymes (acetylcholinesterase and butyrylcholinesterase) linked with Alzheimer's disease in vitro.
Saliu JA; Olabiyi AA
Pharm Biol; 2017 Dec; 55(1):252-257. PubMed ID: 27927065
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological activity of new donepezil-hydrazinonicotinamide hybrids.
Zurek E; Szymański P; Mikiciuk-Olasik E
Drug Res (Stuttg); 2013 Mar; 63(3):137-44. PubMed ID: 23447117
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and pharmacological evaluation of donepezil-based agents as new cholinesterase/monoamine oxidase inhibitors for the potential application against Alzheimer's disease.
Li F; Wang ZM; Wu JJ; Wang J; Xie SS; Lan JS; Xu W; Kong LY; Wang XB
J Enzyme Inhib Med Chem; 2016; 31(sup3):41-53. PubMed ID: 27384289
[TBL] [Abstract][Full Text] [Related]
10. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro.
Ogura H; Kosasa T; Kuriya Y; Yamanishi Y
Methods Find Exp Clin Pharmacol; 2000 Oct; 22(8):609-13. PubMed ID: 11256231
[TBL] [Abstract][Full Text] [Related]
11. Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
Camps P; Formosa X; Galdeano C; Gómez T; Muñoz-Torrero D; Scarpellini M; Viayna E; Badia A; Clos MV; Camins A; Pallàs M; Bartolini M; Mancini F; Andrisano V; Estelrich J; Lizondo M; Bidon-Chanal A; Luque FJ
J Med Chem; 2008 Jun; 51(12):3588-98. PubMed ID: 18517184
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Bolea I; Juárez-Jiménez J; de Los Ríos C; Chioua M; Pouplana R; Luque FJ; Unzeta M; Marco-Contelles J; Samadi A
J Med Chem; 2011 Dec; 54(24):8251-70. PubMed ID: 22023459
[TBL] [Abstract][Full Text] [Related]
13. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs.
Kryger G; Silman I; Sussman JL
Structure; 1999 Mar; 7(3):297-307. PubMed ID: 10368299
[TBL] [Abstract][Full Text] [Related]
14. Targeting Alzheimer's disease by investigating previously unexplored chemical space surrounding the cholinesterase inhibitor donepezil.
van Greunen DG; Cordier W; Nell M; van der Westhuyzen C; Steenkamp V; Panayides JL; Riley DL
Eur J Med Chem; 2017 Feb; 127():671-690. PubMed ID: 27823887
[TBL] [Abstract][Full Text] [Related]
15. Sulfonamides as multifunctional agents for Alzheimer's disease.
Bag S; Tulsan R; Sood A; Cho H; Redjeb H; Zhou W; LeVine H; Török B; Török M
Bioorg Med Chem Lett; 2015 Feb; 25(3):626-30. PubMed ID: 25537270
[TBL] [Abstract][Full Text] [Related]
16. Donepezil-ferulic acid hybrids as anti-Alzheimer drugs.
Benchekroun M; Ismaili L; Pudlo M; Luzet V; Gharbi T; Refouvelet B; Marco-Contelles J
Future Med Chem; 2015; 7(1):15-21. PubMed ID: 25582330
[TBL] [Abstract][Full Text] [Related]
17. Pyridonepezils, new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease: synthesis, biological assessment, and molecular modeling.
Samadi A; Estrada M; Pérez C; Rodríguez-Franco MI; Iriepa I; Moraleda I; Chioua M; Marco-Contelles J
Eur J Med Chem; 2012 Nov; 57():296-301. PubMed ID: 23078965
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease.
Liston DR; Nielsen JA; Villalobos A; Chapin D; Jones SB; Hubbard ST; Shalaby IA; Ramirez A; Nason D; White WF
Eur J Pharmacol; 2004 Feb; 486(1):9-17. PubMed ID: 14751402
[TBL] [Abstract][Full Text] [Related]
19. Does caffeine influence the anticholinesterase and antioxidant properties of donepezil? Evidence from in vitro and in vivo studies.
Oboh G; Ogunsuyi OB; Olonisola OE
Metab Brain Dis; 2017 Apr; 32(2):629-639. PubMed ID: 28091956
[TBL] [Abstract][Full Text] [Related]
20. Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor.
Sugimoto H; Ogura H; Arai Y; Limura Y; Yamanishi Y
Jpn J Pharmacol; 2002 May; 89(1):7-20. PubMed ID: 12083745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
